Sac-TMT在经化疗和免疫检查点抑制剂治疗后进展的晚期或转移性尿路上皮癌中的初步结果
该1/2期研究队列9纳入49例经铂类化疗和PD-1/PD-L1抑制剂治疗后进展的晚期或转移性尿路上皮癌患者,接受sac-TMT 5 mg/kg每2周静脉给药。确认客观缓解率为31%(95%CI 18%-45%),疾病控制率71%(95%CI 57%-83%),中位无进展生存期5.5个月,中位总生存期12.1个月。3/4级治疗相关不良事件发生率为63%,最常见为贫血(41%),安全性总体可控。
要点
- 经多线治疗的晚期尿路上皮癌患者中,sac-TMT单药确认ORR达31%,DCR达71%。
- 中位PFS为5.5个月,中位OS为12.1个月,12个月持续缓解概率为53%。
- 3/4级治疗相关不良事件发生率63%,以血液学毒性为主,无5级事件或发热性中性粒细胞减少。
核心结论
- sac-TMT 5 mg/kg每2周单药在经重度治疗的晚期或转移性尿路上皮癌患者中显示出有前景的抗肿瘤活性和可控的安全性,值得进一步评估。
研究设计与样本
- 1/2期2870-001/KL264-01研究队列9的初步结果,纳入49例经至少一线铂类化疗和抗PD-1/PD-L1治疗后进展的局部晚期或转移性尿路上皮癌患者。
- sac-TMT 5 mg/kg每2周静脉给药,直至疾病进展、不可耐受毒性或受试者/医生决定。
- 主要终点为研究者根据RECIST v1.1评估的客观缓解率,次要终点包括缓解持续时间、无进展生存期、总生存期和安全性。
主要发现
- 数据截止2025年2月17日,49例接受治疗,37例(76%)既往接受过≥2线治疗,中位随访18.8个月。
- 确认ORR为31%(95%CI 18%-45%),DCR为71%(95%CI 57%-83%)。
- 中位DOR未达到(范围2.1-22.2+个月),12个月持续缓解概率为53%。
- 中位PFS为5.5个月(95%CI 3.6-7.2个月),中位OS为12.1个月(95%CI 9.9-15.3个月),18个月PFS率和OS率分别为26%和33%。
- 3/4级治疗相关不良事件发生于31例(63%),最常见(≥5%)为贫血(41%)、中性粒细胞计数降低(35%)、白细胞计数降低(20%)、口腔炎(12%)和血小板计数降低(8%);无5级治疗相关不良事件或发热性中性粒细胞减少事件。
关键数值与推荐
- 确认ORR 31%(95%CI 18%-45%),DCR 71%(95%CI 57%-83%)。
- 中位PFS 5.5个月(95%CI 3.6-7.2个月),中位OS 12.1个月(95%CI 9.9-15.3个月)。
- 3/4级治疗相关不良事件发生率63%,贫血41%,中性粒细胞计数降低35%。
临床怎么用
- 对于经铂类化疗和免疫检查点抑制剂治疗后进展的晚期或转移性尿路上皮癌患者,sac-TMT 5 mg/kg每2周单药可作为候选治疗选择。
- 治疗期间需重点监测血液学毒性(贫血、中性粒细胞减少、白细胞减少、血小板减少)和口腔炎。
局限性
- 为1/2期研究的单臂队列初步结果,样本量49例,缺乏随机对照。
- 中位DOR未达到,随访时间仍有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trophoblast cell-surface antigen 2 (TROP2) is overexpressed in advanced or metastatic urothelial cancer (UC), representing a promising therapeutic target. Sacituzumab tirumotecan (sac-TMT) is a TROP2-directed antibody-drug conjugate with a unique, bifunctional linker that maximizes payload delivery to tumor cells. We present preliminary results for sac-TMT monotherapy from cohort 9 of the phase 1/2 2870-001/KL264-01 study in participants with advanced or metastatic UC. PARTICIPANTS AND METHODS: Eligible participants with locally advanced or metastatic UC and disease progression on one or more prior line of platinum-based chemotherapy and anti-programmed cell death protein 1/programmed cell death-ligand 1 therapy received sac-TMT 5 mg/kg intravenously every 2 weeks until disease progression, unacceptable toxicity, or participant/physician decision. The primary endpoint was investigator-assessed objective response rate (ORR) per RECIST version 1.1. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: By data cut-off (17 February 2025), 49 participants were treated with sac-TMT; 37 (76%) had received two or more prior lines of therapy. Median follow-up for this analysis was 18.8 months. The confirmed ORR was 31% [95% confidence interval (CI), 18% to 45%] and the disease control rate was 71% (95% CI 57% to 83%). Median DOR was not reached [range 2.1-22.2+ (+ indicates censored data for the longest DOR, suggesting that patients may have achieved longer remission duration) months], and the 12-month probability of sustained response was 53%. Median PFS and OS were 5.5 months (95% CI 3.6-7.2 months) and 12.1 months (95% CI, 9.9-15.3 months), with 18-month rates of 26% and 33%, respectively. Grade 3/4 treatment-related adverse events (AEs) occurred in 31 participants (63%), and the most common (≥5%) were anemia (41%), decreased neutrophil count (35%), decreased white blood cell count (20%), stomatitis (12%), and decreased platelet count (8%). There were no grade 5 treatment-related AEs or febrile neutropenia events. CONCLUSIONS: Sac-TMT 5 mg/kg monotherapy every 2 weeks demonstrated promising antitumor activity in participants with heavily pretreated advanced or metastatic UC, with a manageable safety profile, warranting further evaluation of sac-TMT in this population.
引用
- Zhu Y, Jiang S, Shi Y, et al. Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors. Ann Oncol. 2025. PMID: 41276258. doi:10.1016/j.annonc.2025.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。